How would you approach a patient with advanced stage DLBCL with a single-site of residual FDG-avid disease after completion of R-CHOP in the frontline setting?
Would you consider this refractory disease and go on to salvage regimen and auto-SCT, or is there a role for definitive XRT to the site of residual disease?
Answer from: Medical Oncologist at Academic Institution
First would be to assess the residual activity level (e.g. PS 4 or 5), as sometimes a short-interval PET may show improvement. If concern is for residual disease in setting of PET showing partial response, I would consider biopsy of the residual site prior to making any changes in therapy.
On...
Sign in or Register to read more